We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations

By LabMedica International staff writers
Posted on 16 Sep 2019
Print article
Image: Circulating tumor cell-free DNA (ctDNA) is found in serum and plasma fractions from blood. The mechanism of ctDNA release is unknown, though apoptosis, necrosis, and active secretion from tumor cells have been hypothesized (Photo courtesy of Wikimedia Commons).
Image: Circulating tumor cell-free DNA (ctDNA) is found in serum and plasma fractions from blood. The mechanism of ctDNA release is unknown, though apoptosis, necrosis, and active secretion from tumor cells have been hypothesized (Photo courtesy of Wikimedia Commons).
Results published in a recent paper suggested that liquid biopsy – specifically analysis of cell-free tumor DNA (ctDNA) – may capture the genetic diversity of acquired drug resistance better than classical surgical biopsy of the tumor.

The effectiveness of ctDNA versus standard single-lesion tumor biopsies has not been directly compared in larger-scale prospective cohorts of patients receiving targeted therapy. Therefore, investigators at the Broad Institute of MIT and Harvard (Boston MA, USA) and their colleagues undertook a prospective study of a cohort of 42 patients with molecularly defined gastrointestinal cancers and acquired resistance to targeted therapy.This study was included in a five-year collaboration that analyzed tumors before and after the onset of drug resistance.

Tumors were analyzed using both liquid and tissue biopsies procedures. The investigators employed a suite of computational tools developed at the Broad Institute, known as PhylogicNDT, to analyze tumor DNA and resistance mutations.

Direct comparison of ctDNA versus tumor biopsy revealed that ctDNA more frequently identified clinically relevant resistance alterations and multiple resistance mechanisms, detecting resistance alterations not found in the matched tumor biopsy in 78% of cases. Whole-exome sequencing of serial ctDNA, tumor biopsies and rapid autopsy specimens elucidated substantial geographic and evolutionary differences across separate tumors.

"This study is the largest to date to directly compare liquid biopsy to tumor biopsy in the setting of cancer resistance," said senior author Dr. Ryan Corcoran, assistant professor of medicine at Harvard Medical School. "Our findings suggest that liquid biopsy may be the preferred clinical modality for assessing how patients' tumors have evolved after they have become resistant to therapy."

The investigators proposed that the data collected in this study indicated that acquired resistance was frequently characterized by profound tumor heterogeneity, and that the emergence of multiple resistance alterations in an individual patient may represent the “rule” rather than the “exception.”

The study was published in the September 9, 2019, online edition of the journal Nature Medicine.

Related Links:
Broad Institute

Gold Supplier
ADAMTS13 Activity Assay
HemosIL ACUSTAR ADAMTS13 Activity Assay
New
Digital Test Reader
ellume•lab
New
Silver Supplier
Chromogenic Medium
CHROMagar Candida Plus
New
SARS-CoV-2 Antibody ELISA Kit
SARS-CoV-2 N-Protein Salivary IgG ELISA Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: Primary angle closure glaucoma can cause permanent blindness if not treated quickly. A highly sensitive genetic test has been developed (Photo courtesy of Flinders University)

Highly Sensitive Genetic Test for Glaucoma Developed

In open-angle glaucoma, the angle in the eye where the iris meets the cornea is as wide and open as it should be, but the eye’s drainage canals become clogged over time, causing an increase in internal... Read more

Industry

view channel
Illustration

ELITechGroup Acquires Freezing Point Osmometry Provider GONOTEC

ELITechGroup (Puteaux, France) has acquired GONOTEC (Berlin, Germany), thus uniting two osmometry market leaders. The acquisition will also provides the industry with a full range of osmometry solutions... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.